Comparison of the pleiotropic effect of atorvastatin and rosuvastatin on postmenopausal changes in bone turnover: A randomized comparative study

• Published in: Medicine (Baltimore) 2024-05, Vol.103 (19), p.e38122-e38122
• Main Authors: Braszak-Cymerman, Anna, Walczak, Marta K, Oduah, Mary-Tiffany, Ludziejewska, Aleksandra, Bryl, Wiesław
• Format: Article
• Language: English
• Subjects: Atorvastatin - pharmacology; Atorvastatin - therapeutic use; Biomarkers - blood; Bone Remodeling - drug effects; Clinical Trial/Experimental Study; Collagen Type I - blood; Dyslipidemias - blood; Dyslipidemias - drug therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Middle Aged; Osteoporosis, Postmenopausal - drug therapy; Postmenopause - drug effects; Rosuvastatin Calcium - administration & dosage; Rosuvastatin Calcium - therapeutic use
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000038122

Statins are the first-line treatment for dyslipidemia, which is a major modifiable risk factor for atherosclerotic cardiovascular disease. Studies have shown that in addition to the beneficial lipid-lowering effect, statins also exhibit a number of pleiotropic effects that may find application in other diseases, including osteoporosis. This study aimed to assess the effect of statins on bone turnover, as measured by the concentration of bone turnover markers, and to compare the effect of atorvastatin as a lipophilic statin and rosuvastatin as a hydrophilic statin. This study included 34 postmenopausal women aged  .05) - for all patients or subgroups according to statin use. Analysis of the results showed that after 12 months, there was a statistically significant decrease in N-terminal propeptide of procollagen type I concentration in all subjects (P = .004). By statin subgroup, a statistically significant decrease in N-terminal propeptide of procollagen type I was observed only in patients receiving rosuvastatin (P = .012) and not in those receiving atorvastatin (P = .25). Moreover, changes in bone turnover markers did not correlate with changes in lipid concentrations. These results may indicate the superiority of atorvastatin over rosuvastatin in inhibiting adverse changes in bone turnover in postmenopausal women. Confirmed by studies involving a larger population, the observed differences might find particular applications in clinical practice, and the choice of atorvastatin over rosuvastatin for women could be considered in the early postmenopausal period to reduce the risk of osteoporosis and subsequent osteoporotic fractures.